Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Saturday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

BTX opened at $6.74 on Friday. The stock’s 50 day moving average price is $3.38 and its 200-day moving average price is $1.72. Brooklyn ImmunoTherapeutics has a one year low of $6.35 and a one year high of $8.31. The stock has a market cap of $396.49 million, a price-to-earnings ratio of -2.97 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Announces Dividend

The firm also recently disclosed a monthly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, March 14th will be given a $0.0862 dividend. This represents a $1.03 annualized dividend and a yield of 15.34%. The ex-dividend date of this dividend is Friday, March 14th. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is presently -38.33%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.